Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantI
Invus
Activity from announced rounds
Activity in this selectionOct 21, 2026 · Sep 22, 2026
Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $385M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionPrecision Neuroscience
Develops a brain-computer interface intended to help people with paralysis operate digital devices.
$250MSeries D
Participant